Osmotica Pharm Us Company Profile
What is the competitive landscape for OSMOTICA PHARM US
OSMOTICA PHARM US has nine approved drugs.
There are five US patents protecting OSMOTICA PHARM US drugs.
Summary for Osmotica Pharm Us
| US Patents: | 5 |
| Tradenames: | 9 |
| Ingredients: | 8 |
| NDAs: | 9 |
Drugs and US Patents for Osmotica Pharm Us
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-003 | Jun 23, 2022 | RX | Yes | No | 10,265,308 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Osmotica Pharm Us | VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022104-002 | May 20, 2008 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Osmotica Pharm Us | VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022104-003 | May 20, 2008 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-007 | Jun 23, 2022 | RX | Yes | Yes | 9,855,258 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Osmotica Pharm Us | RELEXXII | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 216117-003 | Jun 23, 2022 | RX | Yes | No | 9,707,217 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Osmotica Pharm Us | VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022104-001 | May 20, 2008 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Osmotica Pharm Us
International Patents for Osmotica Pharm Us Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 109157 | ⤷ Start Trial |
| Canada | 2992767 | ⤷ Start Trial |
| Uruguay | 37344 | ⤷ Start Trial |
| Chile | 2017001919 | ⤷ Start Trial |
| Argentina | 109157 | ⤷ Start Trial |
| Chile | 2017001919 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Osmotica Pharm Us Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0296560 | SPC/GB97/023 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 |
| 0296560 | 2/1998 | Austria | ⤷ Start Trial | PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
